People | December 04, 2025
Jubilant Pharmova appoints Daniel J. O Connor as CEO of Jubilant Therapeutics
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Now a test that offers new precision in prostate cancer detection
Patients can now get the starting 2.5 mg dose for $299 per month
LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Subscribe To Our Newsletter & Stay Updated
